Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient ... PR Newswire (press release) The first clinical trial to directly compare rituximab with the new anti-CD20 monoclonal antibody obinutuzumab for the treatment of relapsed non-Hodgkin lymphoma (NHL) has shown higher response rates for patients treated with the novel therapy. ... |
